Scientists from the United Kingdom and Russia are teaming up for a trial test of the Sputnik V and Oxford-AstraZeneca vaccines. The idea is to see whether mixing the two vaccines can result in a better immune response against Covid-19.
Oxford recently made a publication that showed success for their dose during trials.
Researchers are still collecting the effectiveness of the vaccine in older age groups as they await approval from UK regulator MHRA.
AstraZeneca intends to explore a combination of its jab with other adenovirus vaccines to see if results in a stronger immune response and greater protections.
Both the Sputnik V and Oxford vaccines introduce a harmless part of the genetic code of the Covid-19 virus into the body. The body thus develops stronger immunity, rendering a second or third jab less effective. This explains why Oxford has achieved more progress in issuing out half a dose then a full one - rather than two full doses. Several other vaccine combinations are planned in an effort to approach the challenge from different angles.
The Oxford vaccine was made in Britain in partnership with AstraZeneca while Russia’s Sputnik vaccine was developed by Gamaleya Research Institute in Moscow. Their similarities stem from their underlying Sars-CoV-2 spike protein.
This means they work differently when compared to their Pfizer-BioNTech counterparts which are now approved in Saudi Arabia, Canada, Bahrain, and the United Kingdom. Early results from late-stage Sputnik trials reveal promising results. Russia is among the first countries to register a Covid-19 vaccine despite only testing it on a few people. The vaccine is now available for all Russians in a mass vaccination campaign.